Navigation Links
Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
Date:8/19/2007

KING OF PRUSSIA, Pa., Aug. 2 /PRNewswire/ -- Cytokine PharmaSciences, Inc. (CPSI) today revealed that recent experiments with its small-molecule MIF inhibitors showed oral efficacy in animal models. Based on these results, the Company announced that it is advancing one of these compounds into preclinical development.

Macrophage Migration Inhibitory Factor, or MIF, is linked to many conditions, including arthritis, asthma, cancer, sepsis, inflammatory bowel disease and various infections and autoimmune disorders. Neutralization of MIF biological activity has been shown to have a protective effect against these diseases. CPSI has an extensive patent portfolio focused on MIF, covering various methods for neutralization, including small molecules. These compounds were recently shown to be effective in animal models of multiple sclerosis (MS) and arthritis when administered orally.

The MS animal experiments were conducted in the laboratories of Dr. Abhay Satoskar and Dr. Caroline C. Whitacre, both of Ohio State University in Columbus, OH. Dr. Satoskar stated: "The therapeutic efficacy of these compounds was impressive with no outward signs of toxicity. These findings indicate that small-molecule MIF inhibitors are viable drug candidates for treating other autoimmune and inflammatory diseases in which MIF has been identified as a pathogenic factor." Dr. Whitacre adds: "The inhibitors were especially effective in treating disease that had already started, which is traditionally the most difficult hurdle for a new therapy. We are very encouraged by these results."

The arthritis experiments were conducted under the guidance of Drs. Thais M. Sielecki and Vidal F. de la Cruz of Cytokine PharmaSciences, Inc. Dr. Sielecki observed: "We are encouraged to have a small molecule MIF inhibitor that is orally active. MIF is an important target in many diseases and an oral treatment is a definite advantage." Dr. Sielecki will present the MS and arthritis results at the annual American Chemical Society conference on August 22, 2007, in Boston, MA.

Cytokine PharmaSciences is a biopharmaceutical company located in King of Prussia (near Philadelphia), Pennsylvania. The company licenses technologies from academia and other sources, develops products from those technologies and outlicenses the products to third parties for marketing. For more information, visit to http://www.cytokinepharmasciences.com .


'/>"/>
SOURCE Cytokine PharmaSciences, Inc.

Copyright©2007 PR Newswire.

Related medicine technology :

1. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
2. Data Presented at AACR Meeting Shows Peregrines Immunocytokine Fusion Proteins Reduce Growth of B-Cell Lymphoma Tumors by 85% in Preclinical Studies
3. Cytokinetics Announces Non-clinical Data to be Presented at the 2007 AACR Annual Meeting
4. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
5. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
6. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
7. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
8. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
9. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
10. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
11. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/4/2017)... OBP Medical , a leading ... today announced regulatory approval from Brazil,s ... Nacional de Vigilância Sanitária (ANVISA)) to market ... with integrated LED light source and smoke evacuation ... of a tissue pocket or cavity during surgical ...
(Date:10/2/2017)... Denmark , Oct. 2, 2017 The Rebound ... in the struggle to reverse the tide of prescription drug ... for regulating their medicine intake and stepping down their dosage ... set to launch in December 2017; the first 100,000 people ... Learn more at http://www.rebound-solution.com/ ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... established the certification process to promote standards of excellence for the field of ... scheduled for March 22 – 25, 2018 in Orlando, Florida at the Omni ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton ... staged a mock evacuation of the facility as part of a disaster drill on ... Echo Hose EMS and Shelton City Emergency Manager, as well as the Connecticut ...
(Date:10/13/2017)... Milford, NJ (PRWEB) , ... October 13, 2017 , ... ... weekend at scenic Alexandria Park in Milford, NJ. This free event, sponsored by ... and physical activity. The fun run is geared towards children of all ages; ...
(Date:10/13/2017)... ... , ... “The Journey: From the Mountains to the Mission Field”: the story ... the Philippines. “The Journey: From the Mountains to the Mission Field” is the creation ... has taught all ages and currently teaches a class of ladies at her church, ...
(Date:10/12/2017)... ... October 12, 2017 , ... Planet Fitness, one of the ... today its plans to open a flagship location in Covington, LA at 401 N. ... To Go store next to Office Depot in the Holiday Square shopping center. Its ...
Breaking Medicine News(10 mins):